Investments
82Portfolio Exits
17Funds
6Service Providers
1About Decheng Capital
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with innovative technologies and growth-stage healthcare companies.
Decheng Capital Headquarter Location
3000 Sand Hill Road Building 2, Suite 110
Menlo Park, California, 94025,
United States
650-233-0688
Latest Decheng Capital News
Jun 13, 2022
BOULDER — As the life sciences industry in the area continues to bloom, Watchmaker Genomics Inc., one of the newer companies in the region has completed a Series A funding round as it prepares to ramp up its research and development capabilities and expand its workforce. Watchmaker Genomics closed its $40 million Series A this month, bringing its fundraising total to $53.5 million since its founding in 2019. The round was led by Decheng Capital with co-investment from Eclipse Ventures. Watchmaker develops reagents that are used in genetic testing, primarily for cancer tumor profiling. They are also used in testing inherited and infectious diseases. The company launched its first product in 2020 and has since become profitable, with 175% year-over-year revenue growth. Watchmaker CEO Trey Foskett told BizWest that the company’s founders had various backgrounds in genetic engineering, manufacturing, computational biology and more. They all participated in early research of the tools and technologies that Watchmaker now uses, and they shared a vision for how those could be practically used. “Now we see that research translate into true clinical applications,” Foskett said. “These markets have gotten very large over the past 10 to 15 years. The diversity of applications has just blossomed.” Foskett said Watchmaker will use the capital it raised in the Series A to expand its commercial channels and manufacturing capacity while developing new products for clinical sequencing applications, such as single-cell analysis, epigenetics and cell-free DNA. The company will also accelerate its workforce growth, Foskett said. Watchmaker started with three employees. It now has about 90, with plans to expand to 150 by the end of the year. Foskett said Watchmaker is thrilled to be at the heart of the explosion of the Boulder life sciences industry. Watchmaker is located in Flatiron Park, the life sciences campus that sold for $625 million in April, the richest real estate transaction in Colorado history. The buyer, BioMed Realty LLC, is the largest private life sciences real estate company in the county. “It’s a nice tie-in with the investment we’re making in ourselves,” Foskett said. “Nationally, from a life sciences perspective, there’s a lot of capital coming into the Front Range. We’re right in the bullseye for that thesis. We want to see a critical mass of life sciences companies here.” BOULDER — As the life sciences industry in the area continues to bloom, Watchmaker Genomics Inc., one of the newer companies in the region has completed a Series A funding round as it prepares to ramp up its research and development capabilities and expand its workforce. Watchmaker Genomics closed its $40 million Series A this month, bringing its fundraising total to $53.5 million since its founding in 2019. The round was led by Decheng Capital with co-investment from Eclipse Ventures. Watchmaker develops reagents that are used in genetic testing, primarily for cancer tumor profiling. They are also used in testing inherited and… This article has been intentionally blurred. You must purchase a subscription to view the rest of this content. Want to See More! ?
Decheng Capital Investments
82 Investments
Decheng Capital has made 82 investments. Their latest investment was in Upstream Bio as part of their Series A on June 6, 2022.
Decheng Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/2/2022 | Series A | Upstream Bio | $200M | Yes | 2 | |
6/2/2022 | Series A | Watchmaker Genomics | $40M | Yes | 5 | |
5/17/2022 | Series B | Mirvie | Yes | 5 | ||
5/12/2022 | Private Equity | |||||
2/18/2022 | Series D |
Date | 6/2/2022 | 6/2/2022 | 5/17/2022 | 5/12/2022 | 2/18/2022 |
---|---|---|---|---|---|
Round | Series A | Series A | Series B | Private Equity | Series D |
Company | Upstream Bio | Watchmaker Genomics | Mirvie | ||
Amount | $200M | $40M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 5 | 5 |
Decheng Capital Portfolio Exits
17 Portfolio Exits
Decheng Capital has 17 portfolio exits. Their latest portfolio exit was Apexigen on March 18, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/18/2022 | Acq - Pending | 2 | |||
9/24/2021 | IPO | Public | 21 | ||
7/22/2021 | Reverse Merger | 4 | |||
Date | 3/18/2022 | 9/24/2021 | 7/22/2021 | ||
---|---|---|---|---|---|
Exit | Acq - Pending | IPO | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 21 | 4 |
Decheng Capital Fund History
6 Fund Histories
Decheng Capital has 6 funds, including Decheng Capital China Life Sciences USD Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
12/31/2015 | Decheng Capital China Life Sciences USD Fund II | Multi-Stage Venture Capital | Closed | 2 | |
6/6/2013 | Decheng Capital China Life Sciences USD Fund I LP | ||||
Decheng Investment Fund | |||||
Decheng Capital Global Life Sciences Fund IV | |||||
Decheng Capital China Life Sciences USD Fund III |
Closing Date | 12/31/2015 | 6/6/2013 | |||
---|---|---|---|---|---|
Fund | Decheng Capital China Life Sciences USD Fund II | Decheng Capital China Life Sciences USD Fund I LP | Decheng Investment Fund | Decheng Capital Global Life Sciences Fund IV | Decheng Capital China Life Sciences USD Fund III |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | |||||
Sources | 2 |
Decheng Capital Service Providers
1 Service Provider
Decheng Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel | General Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Decheng Capital Team
3 Team Members
Decheng Capital has 3 team members, including current Founder, Managing Director, Min Cui.
Name | Work History | Title | Status |
---|---|---|---|
Min Cui | Founder, Managing Director | Current | |
Xiangmin c | Bay City Capital | Managing Director | Current |
Min Cui | Managing Director | Current |
Name | Min Cui | Xiangmin c | Min Cui |
---|---|---|---|
Work History | Bay City Capital | ||
Title | Founder, Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.